|Courtesy of St. Jude Medical|
St. Jude Medical ($STJ) is expanding its cardiac resynchronization therapy (CRT) portfolio with SyncAV CRT software, which just received CE mark approval. The software builds on the company's MultiPoint Pacing tech.
This software algorithm was designed keeping heart failure patients who are unresponsive to other pacing options in mind. The tech automatically adjusts pacing based on real-time changes in a patient's cardiac condition. It could help doctors improve on treatments for those who respond well to traditional CRT, the company noted.
CRT works by sending electrical impulses to the heart to stimulate ventricles to beat in sync. While CRT can address heart failure, it doesn't work well in every case.
"The SyncAV CRT algorithm dynamically individualizes programming to work towards providing patients with the right settings at the right time helping offer the best possible outcome for even our most complex patients," said Timothy Betts, consultant cardiologist and electrophysiologist at the Oxford Heart Centre in the John Radcliffe Hospital, in the announcement. "Our goal is to utilize the technology to improve outcomes while offering patients who do not respond to therapy with additional options for treatment."
St. Jude Medical also received CE mark approval for the Quadra Assura MP CRT-Defibrillator, which gives patients unrestricted access to MRI diagnostic testing.
The organization presented results from its investigational device exemption clinical study on the MultiPoint Pacing technology--which included these newly approved additional techs--at CARDIOSTIM-EHRA EUROPACE 2016. St. Jude Medical explained that the study met its primary endpoints for safety and efficacy.
St. Jude Medical earned FDA approval for its MultiPoint Pacing technology in February of this year.
- here's the press release